Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 20.77M | 20.60M | 22.12M | 21.94M | 48.48M |
| Total Receivables | 759.60K | 753.60K | 420.90K | 417.40K | 7.61M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 562.40K | 558.00K | 1.16M | 1.15M | 750.70K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 22.09M | 21.92M | 23.71M | 23.51M | 56.84M |
|
|
|||||
| Total Current Assets | 22.09M | 21.92M | 23.71M | 23.51M | 56.84M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 22.09M | 21.92M | 23.71M | 23.51M | 56.84M |
|
|
|||||
| Total Accounts Payable | -- | -- | -- | -- | -- |
| Total Accrued Expenses | -- | -- | -- | -- | 1.14M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | 247.17M |
| Total Finance Division Other Current Liabilities | 1.60M | 1.59M | 1.21M | 1.20M | 9.74M |
| Total Other Current Liabilities | 1.60M | 1.59M | 1.21M | 1.20M | 9.74M |
| Total Current Liabilities | 1.60M | 1.59M | 1.21M | 1.20M | 258.06M |
|
|
|||||
| Total Current Liabilities | 1.60M | 1.59M | 1.21M | 1.20M | 258.06M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 1.60M | 1.59M | 1.21M | 1.20M | 258.06M |
|
|
|||||
| Common Stock & APIC | 506.73M | 502.70M | 488.57M | 484.47M | 477.28M |
| Retained Earnings | -525.50M | -521.33M | -501.70M | -497.49M | -714.65M |
| Treasury Stock & Other | 39.26M | 38.95M | 35.62M | 35.32M | 36.15M |
| Total Common Equity | 20.49M | 20.33M | 22.49M | 22.30M | -201.21M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 20.49M | 20.33M | 22.49M | 22.30M | -201.21M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 20.49M | 20.33M | 22.49M | 22.30M | -201.21M |
|
|
|||||